FDA Clears Emerging AI-Enabled Software for Cardiac Ultrasound
Recent research has demonstrated that the AI software HeartFocus enabled novice health-care providers to achieve greater than 85 percent agreement with expert sonographers in assessing echocardiographic parameters.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the AI-powered echocardiography HeartFocus software, which reportedly allows health-care providers with limited echocardiography experience to obtain heart scans.
In addition to offering quality and precision indicators via real-time feedback, the HeartFocus software provides automated recording of top quality clips for 10 ultrasound cardiac reference views, according to DESKi, the manufacturer of the software.
In research presented recently at the American College of Cardiology (ACC) conference, the newly FDA-cleared AI software HeartFocus enabled health-care providers with novice-level echocardiography experience to achieve greater than 85 percent agreement with expert assessment of echocardiographic parameters. (Image courtesy of DESKi.)
In a prospective multicenter trial, presented recently at the American College of Cardiology (ACC) conference, researchers found that health-care providers with limited echocardiography experience who used the HeartFocus software were able to achieve greater than 85 percent agreement with expert sonographers in assessing 12 echocardiographic parameters.
“The clinical trial results and subsequent FDA clearance mark a major step forward in making echocardiography more accessible in the community. Proving that it can successfully guide any healthcare professional to capture high-quality heart scans, HeartFocus will help patients get diagnosed sooner and move more quickly toward the treatment they need,” posited Varinder P. Singh, M.D., the chair of the Department of Cardiology at Lenox Hill Hospital in New York, and senior vice president and executive director of global and international health for Northwell Health.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
AMA Approves Category III CPT Codes for AI-Enabled Perivascular Fat Analysis from CT Scans
April 9th 2025Going into effect in 2026, the new CPT codes may facilitate increased adoption of the CaRi-Heart software for detecting coronary inflammation from computed tomography scans pending FDA clearance of the technology.
